Exploring High Growth Tech Stocks in the United States for September 2024

In This Article:

Over the last 7 days, the market has dropped 4.4%. As for the longer term, the market has risen by 19% in the last year. Looking forward, earnings are forecast to grow by 15% annually. In this context, identifying high growth tech stocks that can capitalize on these trends is crucial for investors seeking robust returns in a dynamic market environment.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

TG Therapeutics

28.39%

43.54%

★★★★★★

Super Micro Computer

20.49%

27.13%

★★★★★★

Sarepta Therapeutics

24.22%

44.94%

★★★★★★

Ardelyx

27.44%

65.92%

★★★★★★

Invivyd

42.91%

70.39%

★★★★★★

G1 Therapeutics

27.57%

57.75%

★★★★★★

Ascendis Pharma

39.71%

68.43%

★★★★★★

Travere Therapeutics

26.72%

68.41%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 249 stocks from our US High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Gambling.com Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Gambling.com Group Limited operates as a performance marketing company for the online gambling industry worldwide and has a market cap of $363.08 million.

Operations: Gambling.com Group Limited generates revenue primarily through its gambling affiliation segment, which brought in $115.74 million. The company operates as a performance marketing entity within the online gambling sector globally.

Gambling.com Group has demonstrated robust financial performance, with second-quarter sales reaching $30.54 million, a 17.6% increase from the previous year. Net income surged to $6.93 million from $0.28 million, reflecting a significant improvement in profitability. The company's R&D expenses are noteworthy; investing heavily in innovation ensures continued growth and competitiveness within the tech sector. Additionally, it revised its full-year revenue guidance upward to between $123 million and $127 million and completed share repurchases worth $19.98 million, indicating strong confidence in its future prospects.

NasdaqGM:GAMB Earnings and Revenue Growth as at Sep 2024
NasdaqGM:GAMB Earnings and Revenue Growth as at Sep 2024

G1 Therapeutics

Simply Wall St Growth Rating: ★★★★★★

Overview: G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing small molecule therapeutics for cancer treatment in the United States, with a market cap of $377.11 million.

Operations: G1 Therapeutics generates revenue primarily from its biotechnology segment, amounting to $58.20 million. The company focuses on developing and commercializing small molecule therapeutics for cancer treatment in the United States.